Fulgent Genetics, Inc
4978 Santa Anita Avenue
Suite 205
Temple City
California
91780
United States
Tel: 626-350-0537
Fax: 626-454-1667
Website: https://www.fulgentgenetics.com/
Email: info@fulgentgenetics.com
About Fulgent Genetics, Inc
Founded in 2011, Fulgent began with two simple ideas; flexibility and affordability. Today, we strive to create the most effective and wide ranging tests on the market. All of this is done in the pursuit of bettering the everyday lives of our customers. We shine brightest when meaningful relationships, passion, and purpose come together.YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Ming Hsieh
CSO: Hanlin Gao
JOBS:
Please click here for Fulgent job opportunities.
FOLLOW FULGENT DIAGNOSTICS:
Tweets by Fulgent Diagnostics
96 articles about Fulgent Genetics, Inc
-
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
2/28/2024
Fulgent Genetics, Inc. today announced financial results for its fourth quarter and full year ended December 31, 2023.
-
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
2/13/2024
Fulgent Genetics, Inc. today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024.
-
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
2/9/2024
CooperSurgical today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.
-
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
11/14/2023
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.
-
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
11/3/2023
Fulgent Genetics, Inc. announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer 38th Annual Meeting in San Diego, CA.
-
Fulgent Reports Third Quarter 2023 Financial Results
11/3/2023
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023.
-
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
10/25/2023
Fulgent Genetics, Inc. today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023.
-
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
10/17/2023
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results before the market opens on Friday, November 3, 2023.
-
Fulgent Reports Second Quarter 2023 Financial Results
8/4/2023
Fulgent Genetics, Inc. today announced financial results for its second quarter ended June 30, 2023.
-
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
7/18/2023
Fulgent Genetics, Inc. today announced that it will release its second quarter 2023 financial results before the market opens on Friday, August 4, 2023.
-
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
6/5/2023
Fulgent Genetics, Inc. today announced data from a Phase 1/1b clinical study of FID-007 in treating various solid tumors was presented in a poster session at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 3, 2023.
-
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
5/18/2023
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”) today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at 8:00 a.m. Central Time on June 3, 2023 in Chicago, Illinois.
-
Fulgent Reports First Quarter 2023 Financial Results
5/5/2023
Fulgent Genetics, Inc. today announced financial results for its first quarter ended March 31, 2023.
-
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
4/20/2023
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its first quarter 2023 financial results before the market opens on Friday, May 5, 2023.
-
Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research
4/11/2023
Mission Bio, Inc. today announced that it has entered into an agreement with Fulgent Genetics (NASDAQ: FLGT), a technology-based company with well-established clinical diagnostic and therapeutic development businesses.
-
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
2/28/2023
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.
-
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
2/28/2023
Fulgent Genetics, Inc., a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, announced the immediate availability of their new Beacon787 expanded carrier screening panel.
-
Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
2/14/2023
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”) today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday, February 28, 2023.
-
Fulgent Expands Board of Directors with Addition of Reggie Groves
1/3/2023
Fulgent Genetics, Inc. announced the addition of Reggie Groves to its board of directors, effective January 3, 2023.
-
Fulgent Genetics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
11/17/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”) today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.